DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR MIPOMERSEN SODIUM
» See Plans and Pricing
All Clinical Trials for Mipomersen Sodium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00362180 | Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration | Completed | Ionis Pharmaceuticals, Inc. | Phase 2 | 2006-07-01 | This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis. In order to enroll subject groups with varying degrees of risk, the study has included multiple cohorts (Cohorts A-G). Additions and removal of cohorts has been accomplished with protocol amendments. |
| NCT00362180 | Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration | Completed | Kastle Therapeutics, LLC | Phase 2 | 2006-07-01 | This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis. In order to enroll subject groups with varying degrees of risk, the study has included multiple cohorts (Cohorts A-G). Additions and removal of cohorts has been accomplished with protocol amendments. |
| NCT00477594 | Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia | Completed | Ionis Pharmaceuticals, Inc. | Phase 2 | 2007-05-01 | The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials. |
| NCT00477594 | Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia | Completed | Kastle Therapeutics, LLC | Phase 2 | 2007-05-01 | The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Mipomersen Sodium
Condition Name
Condition MeSH
Clinical Trial Locations for Mipomersen Sodium
Trials by Country
Clinical Trial Progress for Mipomersen Sodium
Clinical Trial Phase
Clinical Trial Sponsors for Mipomersen Sodium
Sponsor Name
